Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Glucagon, Other Mar 22 | 2021Zealand's Dasiglucagon Approved; March 22-25 CHMP Agenda; Fractyl Enrolls First Patient in T2DM Study; Twist Bioscience Announces Positive Preclinical DataPurchase Blast
$599
Posted in: Insulin Delivery Mar 20 | 2021Omnipod 5 Pivotal Data Meets the Bar and Leaves Room for Further InnovationPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Insulin Delivery, Other Mar 19 | 2021Biocorp Partners to Integrate Mallya into Diabeloop AID System; vTv Initiates New TTP399 Study; Adocia and Sigilon Q4 '20 Earnings UpdatesPurchase Blast$599
Posted in: Glucose Monitoring, Other, SGLT2i Mar 18 | 2021New Implantable CGM Study from Indigo; Gilead/Novo Expand NASH Collaboration; Metacrine Q4 '20 Earnings Update; Cytokinetics to Present GALACTIC-HF Analysis at ACC 2021Purchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Mar 17 | 2021Bigfoot Recieves $57M in Financing; ACC/Novo Partner for T2DM/CVD HCP Education; Amazon Care Telehealth Program Launched NationwidePurchase Blast
$599
Posted in: Insulin Delivery Mar 17 | 2021Insulet to Host Investor Event Following Omnipod 5 Pivotal Data Presentation @ ENDO 2021Purchase Blast
$599
Posted in: Basal Insulin, SGLT2i Mar 16 | 2021Glooko Raises $30M Series D; AZ and BrightInsight Launch Digital Platform; Oramed Randomizes 25% of Patients in Ph3 Oral Insulin TrialPurchase Blast
$599
Posted in: Bolus Insulin Mar 15 | 2021MannKind to Participate in Medicare Part D Senior Savings ModelPurchase Blast
$599
Posted in: Glucagon, Glucose Monitoring Mar 11 | 2021Zealand Q4 '20 Earnings Update; Nemaura Submits for sugarBEAT Reimbursement in GermanyPurchase Blast
$599
Posted in: SGLT2i Mar 10 | 2021Lexicon Confident in Sota HF Label After Entresto Approval; Lexicon Q4 and FY '20 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Other Mar 10 | 2021Lannett Receives FDA Feedback for Bs-glargine; Adocia Initiates Ph2 M1Pram Trial; Vertex Receives Fast Track Designation for VX-880 in T1DM; Welldoc Hires New CMO; Intercept CFO to DepartPurchase Blast
$599
Posted in: Glucagon, Other Mar 09 | 2021Xeris and Dario Q4 and FY '20 Earnings Calls; Lilly Research Collaboration for Diabetes; Metacrine Initiates Ph2a Trial in NASHPurchase Blast
$599
Posted in: Dual/triple agonist, Glucagon, Other Mar 05 | 2021Zealand R&D Day HighlightsPurchase Blast
$599
Posted in: Glucose Monitoring, Other Mar 04 | 2021Senseonics Q4 '20 Earnings Update; Provention Bio Extended Follow-up Data Published; Voluntis Collaborates with Zendesk for Global Customer SupportPurchase Blast
$599
Posted in: Dual/triple agonist Mar 04 | 2021Payback for Lilly as Tirzepatide Beats Ozempic in Ph3 SURPASS-2 H2H TrialPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery, Other Mar 01 | 2021BI and Gubra Partner for Obesity Drug Development; Diabeloop DBLG1 Integrates with Accu-Chek Insight Pump; Tandem Appoints Jordan Pinsker as VP and Medical DirectorPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, GLP-1RA Mar 01 | 2021Viatris Generic Rybelsus in the Pipeline; Viatris 2021 Investor DayPurchase Blast
$599
Posted in: Other, SGLT2i Feb 26 | 2021Thoughts on Sotagliflozin HF Indication after Entresto's PARAGON ApprovalPurchase Blast